Mednet Logo

For patients with high-volume hormone-sensitive prostate cancer, would you consider shortening the docetaxel course to 4 cycles to facilitate better tolerance?

Especially for a patient with excellent disease response/undetectable PSA?
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on

My default here is always evidence-based medicine, in which 6 cycles of docetaxel were given as part of either concurrent triplet therapy (ARASENS or PEACE-1) or sequential triplet therapy (ARCHES, TITAN), without prednisone. For those who develop intolerance, a dose reduction or growth factor suppo...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · Cancer Care Specialists/Renown Oncology/UNR
Answered on

ARASAFE trial- ADT+ Daro + Docetaxel randomization.

50 mg/m² on days 1 and 15 every 2 weeks vs 75 mg/m² every 3 weeks.

The experimental arm had a higher total docetaxel dose but lower grade 3–5 AEs.
Lower grade 3–4 neutropenia/death (NAER).
Significantly improved safety profile.

PSA ≤0.2 ng/mL at wee...

Join for free or sign in to see the full answer